{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:02:16Z","timestamp":1790899336554,"version":"4.1.0"},"reference-count":131,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T00:00:00Z","timestamp":1536451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA154731, P3GM1033336"],"award-info":[{"award-number":["R01CA154731, P3GM1033336"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancer is initiated by mutations in critical regulatory genes; however, its progression to malignancy is aided by non-neoplastic cells and molecules that create a permissive environment known as the tumor stroma or microenvironment (TME). Interleukin 33 (IL-33) is a dual function cytokine that also acts as a nuclear factor. IL-33 typically resides in the nucleus of the cells where it is expressed. However, upon tissue damage, necrosis, or injury, it is quickly released into extracellular space where it binds to its cognate receptor suppression of tumorigenicity 2 (ST2)L found on the membrane of target cells to potently activate a T Helper 2 (Th2) immune response, thus, it is classified as an alarmin. While its role in immunity and immune-related disorders has been extensively studied, its role in tumorigenesis is only beginning to be elucidated and has revealed opposing roles in tumor development. The IL-33\/ST2 axis is emerging as a potent modulator of the TME. By recruiting a cohort of immune cells, it can remodel the TME to promote malignancy or impose tumor regression. Here, we review its multiple functions in various cancers to better understand its potential as a therapeutic target to block tumor progression or as adjuvant therapy to enhance the efficacy of anticancer immunotherapies.<\/jats:p>","DOI":"10.3390\/ijms19092676","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T10:28:57Z","timestamp":1536575337000},"page":"2676","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":110,"title":["The Role of IL-33\/ST2 Pathway in Tumorigenesis"],"prefix":"10.3390","volume":"19","author":[{"given":"Kristen M.","family":"Larsen","sequence":"first","affiliation":[{"name":"Department of Biological Sciences, University of South Carolina, Columbia, SC 29208, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maydelis Karla","family":"Minaya","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of South Carolina, Columbia, SC 29208, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Vaish","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of South Carolina, Columbia, SC 29208, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Marjorette O.","family":"Pe\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences and Center for Colon Cancer Research, University of South Carolina, Columbia, SC 29208, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,9,9]]},"reference":[{"key":"ref_1","unstructured":"Health and Human Services (2016). United States 2016: With Chartbook on Long-Term Trands in Health, US Government Printing Office."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer Statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: Functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nri2692","article-title":"Disease-associated functions of IL-33: The new kid in the IL-1 family","volume":"10","author":"Liew","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/ard.2009.122655","article-title":"IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy","volume":"69","author":"Verri","year":"2010","journal-title":"Ann. Rheum Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1093\/hmg\/ddi323","article-title":"Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis","volume":"14","author":"Shimizu","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"26369","DOI":"10.1074\/jbc.M704916200","article-title":"Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation","volume":"282","author":"Hayakawa","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"423957","DOI":"10.1155\/2014\/423957","article-title":"Interleukin-33 and inflammatory bowel diseases: Lessons from human studies","volume":"2014","author":"Nunes","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1172\/JCI30634","article-title":"IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system","volume":"117","author":"Sanada","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.pharmthera.2011.02.005","article-title":"The IL-33\/ST2 pathway\u2014A new therapeutic target in cardiovascular disease","volume":"131","author":"Miller","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrd2660","article-title":"The IL-33\/ST2 pathway: Therapeutic target and novel biomarker","volume":"7","author":"Kakkar","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Moussion, C., Ortega, N., and Girard, J.P. (2008). The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel \u2018alarmin\u2019?. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003331"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.it.2009.03.003","article-title":"Interleukin-33\u2013cytokine of dual function or novel alarmin?","volume":"30","author":"Haraldsen","year":"2009","journal-title":"Trends Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.0606854104","article-title":"IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo","volume":"104","author":"Carriere","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/embor.2008.145","article-title":"Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket","volume":"9","author":"Roussel","year":"2008","journal-title":"EMBO Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/acn3.47","article-title":"Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis","volume":"1","author":"Zhang","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.4049\/jimmunol.1003080","article-title":"The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription","volume":"187","author":"Ali","year":"2011","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/cmi.2010.3","article-title":"The enigmatic processing and secretion of interleukin-33","volume":"7","author":"Zhao","year":"2010","journal-title":"Cell. Mol. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9021","DOI":"10.1073\/pnas.0812690106","article-title":"The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1","volume":"106","author":"Cayrol","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coi.2014.09.004","article-title":"IL-33: An alarmin cytokine with crucial roles in innate immunity, inflammation and allergy","volume":"31","author":"Cayrol","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaut.2014.02.012","article-title":"Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation","volume":"55","author":"Bessa","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"19420","DOI":"10.1074\/jbc.M901744200","article-title":"Interleukin-33 is biologically active independently of caspase-1 cleavage","volume":"284","author":"Lamacchia","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.bbrc.2009.12.107","article-title":"Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation","volume":"391","author":"Ali","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.immuni.2009.05.007","article-title":"Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases","volume":"31","author":"Luthi","year":"2009","journal-title":"Immunity"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1073\/pnas.1115884109","article-title":"IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G","volume":"109","author":"Lefrancais","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"15502","DOI":"10.1073\/pnas.1410700111","article-title":"Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells","volume":"111","author":"Lefrancais","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1684\/ecn.2012.0320","article-title":"Mechanisms of IL-33 processing and secretion: Differences and similarities between IL-1 family members","volume":"23","author":"Lefrancais","year":"2012","journal-title":"Eur. Cytokine Netw."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0014-5793(89)81679-5","article-title":"A putative protein of a growth specific cDNA from BALB\/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor","volume":"258","author":"Tominaga","year":"1989","journal-title":"FEBS Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0167-4781(92)90125-J","article-title":"Nucleotide sequence of a complementary DNA for human ST2","volume":"1171","author":"Tominaga","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0014-5793(93)81333-U","article-title":"Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1","volume":"318","author":"Yanagisawa","year":"1993","journal-title":"FEBS Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2016.05.004","article-title":"Interleukin-33, friend and foe in type-2 immune responses","volume":"42","author":"Hardman","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/j.1460-2075.1994.tb06367.x","article-title":"Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor","volume":"13","author":"Bergers","year":"1994","journal-title":"EMBO J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1006\/bbrc.1999.1469","article-title":"Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7\/GM","volume":"264","author":"Tominaga","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1006\/bbrc.2001.5306","article-title":"Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V","volume":"285","author":"Tago","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbaexp.2004.08.013","article-title":"Molecular cloning of the chicken ST2 gene and a novel variant form of the ST2 gene product, ST2LV","volume":"1681","author":"Iwahana","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1046\/j.1365-2745.2002.01494.x","article-title":"Expression and function of the ST2 gene in a murine model of allergic airway inflammation","volume":"32","author":"Oshikawa","year":"2002","journal-title":"Clin. Exp. Allergy"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1432-1327.1999.00615.x","article-title":"Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells","volume":"264","author":"Iwahana","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"32689","DOI":"10.1074\/jbc.M112.374876","article-title":"GATA2 is a critical transactivator for the human IL1RL1\/ST2 promoter in mast cells\/basophils: Opposing roles for GATA2 and GATA1 in human IL1RL1\/ST2 gene expression","volume":"287","author":"Baba","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Akimoto, M., and Takenaga, K. (2018). Role of the IL-33\/ST2L axis in colorectal cancer progression. Cell. Immunol.","DOI":"10.1016\/j.cellimm.2017.12.014"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.semcdb.2016.08.007","article-title":"Wounds that heal and wounds that don\u2019t\u2014The role of the IL-33\/ST2 pathway in tissue repair and tumorigenesis","volume":"61","author":"Millar","year":"2017","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.cellsig.2008.05.013","article-title":"TRAF6 is a critical signal transducer in IL-33 signaling pathway","volume":"20","author":"Tago","year":"2008","journal-title":"Cell. Signal."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12026-012-8283-9","article-title":"IL-33\/ST2 axis in inflammation and immunopathology","volume":"52","author":"Milovanovic","year":"2012","journal-title":"Immunol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/bjc.2015.433","article-title":"An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer","volume":"114","author":"Mahmoud","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/ni.2341","article-title":"F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation","volume":"13","author":"Zhao","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1006\/bbrc.1997.6810","article-title":"Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli","volume":"235","author":"Kumar","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8327","DOI":"10.1038\/ncomms9327","article-title":"Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation","volume":"6","author":"Cohen","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/eji.201141417","article-title":"ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma","volume":"41","author":"Jovanovic","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4161\/onci.1.2.18131","article-title":"IL-33\/ST2 axis in innate and acquired immunity to tumors","volume":"1","author":"Jovanovic","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1038\/onc.2011.525","article-title":"Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis","volume":"31","author":"Duthey","year":"2012","journal-title":"Oncogene"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/ijc.28481","article-title":"Interleukin-33\/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells","volume":"134","author":"Jovanovic","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e1063772","DOI":"10.1080\/2162402X.2015.1063772","article-title":"Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells","volume":"5","author":"Xiao","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"18106","DOI":"10.18632\/oncotarget.7635","article-title":"Deletion of IL-33R attenuates VEGF expression and enhances necrosis in mammary carcinoma","volume":"7","author":"Milosavljevic","year":"2016","journal-title":"Oncotarget"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1038\/onc.2014.418","article-title":"Interleukin-33\/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity","volume":"34","author":"Kim","year":"2015","journal-title":"Oncogene"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lu, D.P., Zhou, X.Y., Yao, L.T., Liu, C.G., Ma, W., Jin, F., and Wu, Y.F. (2014). Serum soluble ST2 is associated with ER-positive breast cancer. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-198"},{"key":"ref_59","first-page":"516895","article-title":"The Association of Serum IL-33 and sST2 with Breast Cancer","volume":"2015","author":"Yang","year":"2015","journal-title":"Dis. Mark."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fimmu.2014.00141","article-title":"Significance of interleukin-33 and its related cytokines in patients with breast cancers","volume":"5","author":"Liu","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_61","first-page":"1189","article-title":"Evaluation of the circulating levels of IL-12 and IL-33 in patients with breast cancer: Influences of the tumor stages and cytokine gene polymorphisms","volume":"18","author":"Jafarzadeh","year":"2015","journal-title":"Iran. J. Basic Med. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1080\/08941939.2016.1240270","article-title":"The Role of Interleukin-33 as an Inflammatory Marker in Differential Diagnosis of Idiopathic Granulomatous Mastitis and Breast Cancer","volume":"30","author":"Yigitbasi","year":"2017","journal-title":"J. Investig. Surg"},{"key":"ref_63","unstructured":"American Cancer Society (2018). Cancer Facts and Figures 2018, American Cancer Society."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00262-014-1624-x","article-title":"Dynamics of the IL-33\/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer","volume":"64","author":"Cui","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.bbrc.2014.09.106","article-title":"IL-33\/ST2 pathway contributes to metastasis of human colorectal cancer","volume":"453","author":"Liu","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"E2487","DOI":"10.1073\/pnas.1422445112","article-title":"IL-33 activates tumor stroma to promote intestinal polyposis","volume":"112","author":"Maywald","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e1062966","DOI":"10.1080\/2162402X.2015.1062966","article-title":"The IL-33\/ST2 pathway contributes to intestinal tumorigenesis in humans and mice","volume":"5","author":"Mertz","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/mc.22491","article-title":"IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis","volume":"56","author":"Zhang","year":"2017","journal-title":"Mol. Carcinog."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"19977","DOI":"10.1073\/pnas.0704620104","article-title":"Mast cells are an essential hematopoietic component for polyp development","volume":"104","author":"Gounaris","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10555-011-9286-z","article-title":"The significant role of mast cells in cancer","volume":"30","author":"Khazaie","year":"2011","journal-title":"Cancer Metast. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1073\/pnas.1716804115","article-title":"Mast cells promote small bowel cancer in a tumor stage-specific and cytokine-dependent manner","volume":"115","author":"Saadalla","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1038\/ncomms13589","article-title":"Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment","volume":"7","author":"Akimoto","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1158\/0008-5472.CAN-16-1602","article-title":"IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment","volume":"77","author":"Fang","year":"2017","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1038\/s41598-017-05716-z","article-title":"Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc (Min\/+) mice","volume":"7","author":"He","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/2326-6066.CIR-17-0218","article-title":"Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-gamma-Dependent Manner","volume":"6","author":"Eissmann","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.canlet.2013.03.002","article-title":"Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice","volume":"335","author":"Gao","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4049\/jimmunol.1401344","article-title":"Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells","volume":"194","author":"Gao","year":"2015","journal-title":"J. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1113\/JP275512","article-title":"Injury, repair, inflammation and metaplasia in the stomach","volume":"596","author":"Meyer","year":"2018","journal-title":"J. Physiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/gutjnl-2016-312779","article-title":"A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach","volume":"67","author":"Petersen","year":"2018","journal-title":"Gut"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1593\/tlo.12418","article-title":"High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma","volume":"6","author":"Bergis","year":"2013","journal-title":"Transl. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/hep.27728","article-title":"Tumor-infiltrating, interleukin-33-producing effector-memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survival","volume":"61","author":"Brunner","year":"2015","journal-title":"Hepatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1177\/030006051204000504","article-title":"Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications","volume":"40","author":"Zhang","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Wei, Z.H., Li, Y.Y., Huang, S.Q., and Tan, Z.Q. (2018). Genetic variants in IL-33\/ST2 pathway with the susceptibility to hepatocellular carcinoma in a Chinese population. Cytokine.","DOI":"10.1016\/j.cyto.2018.03.036"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/hep.27687","article-title":"IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism","volume":"61","author":"Yamada","year":"2015","journal-title":"Hepatology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1172\/JCI73742","article-title":"Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation","volume":"124","author":"Li","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_86","unstructured":"U.S. Department of Health and Human Services (2017). United States Cancer Statistics: 1999\u20132014 Incidence and Mortality Web-Based Report, Centers for Disease Control and Prevention and National Cancer Institute."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"G821","DOI":"10.1152\/ajpgi.00178.2010","article-title":"Nuclear expression of interleukin-33 in pancreatic stellate cells","volume":"299","author":"Masamune","year":"2010","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cyto.2012.06.286","article-title":"Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells","volume":"60","author":"Schmieder","year":"2012","journal-title":"Cytokine"},{"key":"ref_89","first-page":"348","article-title":"Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?","volume":"34","author":"Naumnik","year":"2012","journal-title":"Exp. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.7314\/APJCP.2013.14.4.2563","article-title":"Serum IL-33 as a diagnostic and prognostic marker in non-small cell lung cancer","volume":"14","author":"Hu","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.bbrc.2016.09.081","article-title":"IL-33 signaling fuels outgrowth and metastasis of human lung cancer","volume":"479","author":"Wang","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2147\/OTT.S155905","article-title":"Interleukin-33 enhanced the migration and invasiveness of human lung cancer cells","volume":"11","author":"Yang","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"68571","DOI":"10.18632\/oncotarget.19786","article-title":"IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"13462","DOI":"10.18632\/oncotarget.24008","article-title":"Gram-negative bacteria facilitate tumor progression through TLR4\/IL-33 pathway in patients with non-small-cell lung cancer","volume":"9","author":"Sun","year":"2018","journal-title":"Oncotarget"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.lungcan.2015.08.011","article-title":"Circulating IL-33 level is associated with the progression of lung cancer","volume":"90","author":"Kim","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e2057","DOI":"10.1038\/cddis.2015.418","article-title":"Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer","volume":"7","author":"Akimoto","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Yang, M., Feng, Y., Yue, C., Xu, B., Chen, L., Jiang, J., Lu, B., and Zhu, Y. (2018). Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193428"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1038\/s41598-018-20608-6","article-title":"Type 2 Innate Lymphocytes Actuate Immunity Against Tumours and Limit Cancer Metastasis","volume":"8","author":"Saranchova","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"30555","DOI":"10.1038\/srep30555","article-title":"Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33","volume":"6","author":"Saranchova","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"F356","DOI":"10.1152\/ajprenal.00040.2017","article-title":"IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer","volume":"314","author":"Ravichandran","year":"2018","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.molonc.2015.06.004","article-title":"Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways","volume":"10","author":"Tong","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1093\/humrep\/det238","article-title":"Profibrotic interleukin-33 is correlated with uterine leiomyoma tumour burden","volume":"28","author":"Santulli","year":"2013","journal-title":"Hum. Reprod."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/humrep\/des154","article-title":"Serum and peritoneal interleukin-33 levels are elevated in deeply infiltrating endometriosis","volume":"27","author":"Santulli","year":"2012","journal-title":"Hum. Reprod."},{"key":"ref_104","first-page":"9262919","article-title":"Clinical Significance of Serum Interleukin-31 and Interleukin-33 Levels in Patients of Endometrial Cancer: A Case Control Study","volume":"2016","author":"Zeng","year":"2016","journal-title":"Dis. Mark."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12032-014-0143-0","article-title":"Examining IL-33 expression in the cervix of HPV-infected patients: A preliminary study comparing IL-33 levels in different stages of disease and analyzing its potential association with IFN-gamma","volume":"31","author":"Wang","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/path.4226","article-title":"The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma","volume":"231","author":"Chen","year":"2013","journal-title":"J. Pathol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3892\/ol.2016.4626","article-title":"Interleukin-33 in human gliomas: Expression and prognostic significance","volume":"12","author":"Gramatzki","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/neuonc\/not234","article-title":"Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells","volume":"16","author":"Fang","year":"2014","journal-title":"Neuro Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Tada, H., Matsuyama, T., Nishioka, T., Hagiwara, M., Kiyoura, Y., Shimauchi, H., and Matsushita, K. (2016). Porphyromonas gingivalis Gingipain-Dependently Enhances IL-33 Production in Human Gingival Epithelial Cells. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0152794"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4049\/jimmunol.1203328","article-title":"Inflammatory cytokine-mediated evasion of virus-induced tumors from NK cell control","volume":"191","author":"Mishra","year":"2013","journal-title":"J. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.anl.2014.08.007","article-title":"Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue","volume":"41","author":"Ishikawa","year":"2014","journal-title":"Auris Nasus Larynx"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/1066896916633856","article-title":"Interleukin-33 Expression Indicates a Favorable Prognosis in Malignant Salivary Gland Tumors","volume":"24","author":"Rossle","year":"2016","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ajpath.2011.03.010","article-title":"The immune-modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation","volume":"179","author":"Byrne","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/icb.2014.123","article-title":"HPV16 E7 expression in skin induces TSLP secretion, type 2 ILC infiltration and atopic dermatitis-like lesions","volume":"93","author":"Bergot","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1038\/jid.2012.180","article-title":"Novel splice variants of IL-33: Differential expression in normal and transformed cells","volume":"132","author":"Tsuda","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"20078","DOI":"10.1074\/jbc.M111.219089","article-title":"Identification of Constitutively Active Interleukin 33 (IL-33) Splice Variant","volume":"286","author":"Hong","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"eaan8355","DOI":"10.1126\/scisignal.aan8355","article-title":"IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks","volume":"10","author":"Serrels","year":"2017","journal-title":"Sci Signal"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/carcin\/bgy006","article-title":"A novel stromal lncRNA signature reprograms fibroblasts to promote the growth of oral squamous cell carcinoma via LncRNA-CAF\/interleukin-33","volume":"39","author":"Ding","year":"2018","journal-title":"Carcinogenesis"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1172\/JCI77347","article-title":"IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms","volume":"125","author":"Mager","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-13-2797","article-title":"BCR-ABL-induced deregulation of the IL-33\/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients","volume":"74","author":"Levescot","year":"2014","journal-title":"Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.yexcr.2010.04.007","article-title":"KU812 cells provide a novel in vitro model of the human IL-33\/ST2L axis: Functional responses and identification of signaling pathways","volume":"316","author":"Tare","year":"2010","journal-title":"Exp. Cell Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/07357907.2013.764566","article-title":"Decreased plasma levels of IL-33 could contribute to the altered function of Th2 lymphocytes in patients with polycythemia vera and essential thrombocythemia","volume":"31","author":"Gangemi","year":"2013","journal-title":"Cancer Investig."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bjh.12146","article-title":"Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease","volume":"160","author":"Musolino","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000353476","article-title":"Reduction in IL-33 plasma levels might be involved in T cell dysregulation in chronic lymphocytic leukemia","volume":"131","author":"Musolino","year":"2014","journal-title":"Acta Haematol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/eji.201747093","article-title":"IL-33-expanded human Vgamma9Vdelta2 T cells have anti-lymphoma effect in a mouse tumor model","volume":"47","author":"Duault","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.4049\/jimmunol.173.11.6767","article-title":"Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo","volume":"173","author":"Kabelitz","year":"2004","journal-title":"J. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.4049\/jimmunol.175.3.1593","article-title":"Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: The role of exogenous IL-2","volume":"175","author":"Casetti","year":"2005","journal-title":"J. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.4049\/jimmunol.175.8.5471","article-title":"In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model","volume":"175","author":"Sicard","year":"2005","journal-title":"J. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00262-016-1916-4","article-title":"Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma","volume":"66","author":"Zloza","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4049\/jimmunol.1500260","article-title":"TCRVgamma9 gammadelta T Cell Response to IL-33: A CD4 T Cell-Dependent Mechanism","volume":"196","author":"Duault","year":"2016","journal-title":"J. Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.neuroscience.2013.08.026","article-title":"Spinal interleukin-33 and its receptor ST2 contribute to bone cancer-induced pain in mice","volume":"253","author":"Zhao","year":"2013","journal-title":"Neuroscience"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/9\/2676\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:19:36Z","timestamp":1760195976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/9\/2676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,9]]},"references-count":131,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["ijms19092676"],"URL":"https:\/\/doi.org\/10.3390\/ijms19092676","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,9]]}}}